Abstract
The pharmacokinetics of cefuroxime were studied after a single dose of 750 mg was given intravenously to each of 21 male volunteers grouped according to their creatinine clearances; these clearances were 60 to 120, 20 to 59, and less than 20 ml/min per 1.73 m,2 respectively, for groups 1 (12 subjects), 2 (4 subjects), and 3 (5 subjects). Cefuroxime obeyed two-compartment model kinetics in all three groups. Initial serum levels of cefuroxime were approximately 130 microgram/ml in group 1 and 2 and 80 microgram/ml in group 3. the levels then declined rapidly for 0.5 to 1 h after injection. After that time, cefuroxime levels declined more slowly, and the elimination rate became monoexponential. The mean serum half-lives for cefuroxime in groups 2, 2, and 3 were 1.7, 2.4, and 17.6 h, respectively. Mean cefuroxime levels in serum were greater than 8 microgram/ml for 3 h in group 1, for 6 h in group 2, and for 30 h in group 3. Cumulative 24-h urinary excretion accounted for essentially 100% of the dose in group 1 and 2, and for 40% in group 3. Urine levels exceeded the minimal inhibitory concentration for susceptible organisms for more than 12 h in all groups. Cefuroxime distribution characteristics were independent of renal function. In patients with creatinine clearances less than 20 ml/min per 1.73 m2, doses of cefuroxime needs to be reduced. A microbiological disk diffusion assay and a high-pressure liquid chromatography assay for cefuroxime yielded statistically identical results, except for serum levels in uremic patients (group 3).
Full text
PDF![443](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/64087c07bc64/aac00003-0079.png)
![444](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/209abfcfd575/aac00003-0080.png)
![445](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/de0a7e1e5765/aac00003-0081.png)
![446](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/197c4cab5e21/aac00003-0082.png)
![447](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/922ac9d0c3d8/aac00003-0083.png)
![448](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/fa61a4b24465/aac00003-0084.png)
![449](https://cdn.ncbi.nlm.nih.gov/pmc/blobs/497a/181451/529ef3666e6c/aac00003-0085.png)
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aziz N. S., Gambertoglio J. G., Lin E. T., Grausz H., Benet L. Z. Pharmacokinetics of cefamandole using a HPLC assay. J Pharmacokinet Biopharm. 1978 Apr;6(2):153–164. doi: 10.1007/BF01117449. [DOI] [PubMed] [Google Scholar]
- Eykyn S., Jenkins C., King A., Phillips I. Antibacterial activity of cefuroxime, a new cephalosporin antibiotic, compared with that of cephaloridine, cephalothin, and cefamandole. Antimicrob Agents Chemother. 1976 Apr;9(4):690–695. doi: 10.1128/aac.9.4.690. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Foord R. D. Cefuroxime: human pharmacokinetics.. Antimicrob Agents Chemother. 1976 May;9(5):741–747. doi: 10.1128/aac.9.5.741. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Gower P. E., Kennedy M. R., Dash C. H. The effect of Renal Failure and Dialysis on the Pharmacokinetics of Cefuroxime. Proc R Soc Med. 1977;70(Suppl 9):151–157. doi: 10.1177/00359157770700S935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Höffler D., Sassmann M. Pharmacokinetic studies of cefuroxime and dosage recommendations in patients with impaired renal function. Proc R Soc Med. 1977;70(Suppl 9):144–147. doi: 10.1177/00359157770700S933. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jones R. N., Fuchs P. C., Gavan T. L., Gerlach E. H., Barry A. L., Thornsberry C. Cefuroxime, a new parenteral cephalosporin: collaborative in vitro susceptibility comparison with cephalothin against 5,887 clinical bacterial isolates. Antimicrob Agents Chemother. 1977 Jul;12(1):47–50. doi: 10.1128/aac.12.1.47. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kosmidis J., Stathakis C., Anyfantis A., Daikos G. K. Cefuroxime in renal insufficiency: therapeutic results in various infections and pharmacokinetics including the effects of dialysis. Proc R Soc Med. 1977;70(Suppl 9):139–143. doi: 10.1177/00359157770700S932. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Nakagawa K. Phase one clinical study on cefuroxime. Proc R Soc Med. 1977;70(Suppl 9):22–24. doi: 10.1177/00359157770700S905. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Neu H. C., Fu K. P. Cefuroxime, a beta-lactamase-resistant cephalosporin with a broad spectrum of gram-positive and -negative activity. Antimicrob Agents Chemother. 1978 Apr;13(4):657–664. doi: 10.1128/aac.13.4.657. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Norrby R., Brorsson J. E., Seeberg S. Comparative study of the in vitro antibacterial activity of cefoxitin, cefuroxine, and cephaloridine. Antimicrob Agents Chemother. 1976 Mar;9(3):506–510. doi: 10.1128/aac.9.3.506. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Norrby R., Foord R. D., Hedlund P. Clinical and pharmacokinetic studies on cefuroxime. J Antimicrob Chemother. 1977 Jul;3(4):355–362. doi: 10.1093/jac/3.4.355. [DOI] [PubMed] [Google Scholar]
- O'Callaghan C. H., Sykes R. B., Griffiths A., Thornton J. E. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511–519. doi: 10.1128/aac.9.3.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Ryan D. M., O'Callaghan C., Muggleton P. W. Cefuroxime, a new cephalosporin antibiotic: activity in vivo. Antimicrob Agents Chemother. 1976 Mar;9(3):520–525. doi: 10.1128/aac.9.3.520. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Wagner H. Der alloplastische Gelenkflächenersatz am Hüftgelenk. Arch Orthop Unfallchir. 1975;82(2):101–106. [PubMed] [Google Scholar]
- Welling P. G., Craig W. A., Kunin C. M. Prediction of drug dosage in patients with renal failure using data derived from normal subjects. Clin Pharmacol Ther. 1975 Jul;18(1):45–52. doi: 10.1002/cpt197518145. [DOI] [PubMed] [Google Scholar]
- van Dalen R., Vree T. B., Hafkenscheid J. C., Gimbrère J. S. Determination of plasma and renal clearance of cefuroxime and its pharmacokinetics in renal insufficiency. J Antimicrob Chemother. 1979 May;5(3):281–292. doi: 10.1093/jac/5.3.281. [DOI] [PubMed] [Google Scholar]